Stemtrix Corp.
Stemtrix Corp is a R&D BioTech company, producing veterinarian and human medications that treat and prevent infectious diseases, while significantly reducing the use of antibiotics.
Our innovative medicines have an antibacterial effect. Instead of killing the bacteria, we put it into a vegetative state, blocking its ability to cause disease.
Domingo Garcia - COO
- Innovation
- Implementation
Antibiotics are the primary weapon in the fight against infectious diseases. However, their widespread and uncontrolled usage, especially when it comes to rearing farm animals, has given rise to the spread of antibiotic-resistant strains.
With proven traction the investment will be mainly for the R&D laboratory, patents and for expansion through the local manufacturing third-party in Mexico.
Global market for antimicrobials of farm animals.
- Scale: A sustainable project or enterprise working in several contexts, communities or countries that is looking to scale significantly, focusing on increased efficiency
- Biotechnology / Bioengineering
The mission of Stemtrix Corp. is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations.
Global benefit avoiding bacterial resistance in infectious diseases.
The spread of antibiotic-resistant strains.
The widespread and uncontrolled use of antibiotics has given rise to the spread of antibiotic-resistant strains. One of the reasons is the industrial use of antibiotics in the rearing of farm animals, technologically providing for their use to ensure proper productivity.
Stemtrix preparations do not kill, but serve as mediators of the transition of their pathogens from an active state to a vegetative one. Stemtrix is a radical reduction in the use of antibacterial drugs and antibiotics. The drugs are intended for the prevention and treatment of intestinal and other inflammatory infections of a bacterial nature.
The mission of Stemtrix Corp. is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations.
Global benefit avoiding bacterial resistance in infectious diseases.
The spread of antibiotic-resistant strains.
The widespread and uncontrolled use of antibiotics has given rise to the spread of antibiotic-resistant strains. One of the reasons is the industrial use of antibiotics in the rearing of farm animals, technologically providing for their use to ensure proper productivity.
Stemtrix preparations do not kill, but serve as mediators of the transition of their pathogens from an active state to a vegetative one. Stemtrix is a radical reduction in the use of antibacterial drugs and antibiotics. The drugs are intended for the prevention and treatment of intestinal and other inflammatory infections of a bacterial nature.
3 year landscape:
1st stage: We are targeting farm producers of poultry in Mexico, United States, Brazil, Peru, Costa Rica, Colombia, and Argentina, in this order.
2nd stage: We will target swine producers in the United States, Brazil, Mexico, and Colombia.
Number of farm animals using our products.
- Mexico
- Argentina
- Brazil
- Colombia
- Costa Rica
- Peru
- United States
Funding is the main barrier for expansion.
With proven traction the investment will be mainly for the R&D laboratory, patents and for expansion through the local manufacturing third-party in Mexico.
- Solution Team (not registered as any organization)